ArticlePeerJ2025
The CD8
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progresses into an aggressive and lethal entity within five years. The clinical management of recurrent tumors remains limited. Therefore, identifying individual patients who are at a high risk of recurrence is crucial for early clinical monitoring and appropriate medical intervention, which may lead to improved outcomes. OX40 is a dual modulator that stimulates effector T cells and suppresses Tregs. It appears to be an ideal molecule for predicting survival outcomes, surpassing the predictive power of single or combined T cell signatures. It has been shown to act as an independent tumor prognostic predictor in various cancers, including non-small cell lung cancer, melanoma, and colorectal cancer. However, its potential as a prognostic tool for tumor recurrence in NMIBC has yet to be investigated. The present study aimed to investigate the potential value of OX40 as a predictor of recurrence risk in patients with NMIBC. Additionally, its downstream effectors, Foxp3 and CD8, were also evaluated. Tissue samples were collected from a cohort of 110 patients diagnosed with NMIBC. Immunohistochemistry was performed to assess the density of stromal OX40
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.